First-Line Therapy for Advanced Renal Cell Carcinoma: Score-Matched Analysis of Dual Combination Immunotherapy versus Combination of Tyrosine Kinase Inhibitors and Immunotherapy in the TOURS Multicenter Study
Combining immunotherapy with targeted drugs works better than dual immunotherapy for advanced kidney cancer, with surprisingly better safety.
In 324 propensity score-matched intermediate/poor-risk aRCC patients from a multicenter Japanese cohort, IO-TKI combinations demonstrated substantially superior ORR, PFS, and OS over dual IO therapy, supporting IO-TKI as the preferred first-line approach. While AEs were more common with IO-TKI, immune-related toxicities were paradoxically lower, a clinically meaningful safety distinction.
What the study was
- Study design
- Retrospective multicenter propensity score-matched comparative analysis
- Population
- IMDC intermediate/poor-risk advanced RCC patients treated first-line at 4 Japanese institutions (2018-2026)
- Sample size
- 324
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Targeted Oncology
Why it surfaced
Multicenter propensity-matched n=324; IO-TKI superior PFS (17.1 vs 8.4 mo) and OS (51.7 vs 31.5 mo); real-world evidence that directly informs first-line treatment selection in aRCC.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.